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Accepted 25 July 2014With allogeneic hematopoietic cell transplantation (HCT)
for younger patients with acute lymphoblastic leukemia
(ALL) generally reserved for second or subsequent re-
missions (CR2þ) or highly resistant forms in ﬁrst complete
remission, relapse after transplantation remains the most
common source of treatment failure, and prevention of post-
HCT relapse a high priority for research [1]. A key issue in
approaching the problem is deﬁning very high-risk sub-
populations, in whom potentially risky post-HCT in-
terventions could have a positive impact on survival. It is well
established that patients with ALL going to transplantation
with detectable minimal residual disease (MRD) greater than
.1% by ﬂow cytometry or >104 by PCR just before trans-
plantation are at increased risk of relapse [2,3]. It has also
been noted that patients with increasing levels of recipient
chimerism after transplantation are at high risk for relapse
[4], and many transplantation physicians now routinely
intervene based upon these measures. Which approach best
informs intervention, when and how to intervene, and
whether post-HCT intervention signiﬁcantly improves out-
comes remain uncertain.
In this edition of Biology of Blood and Marrow Trans-
plantation, Terwey et al. give us insight into many of these
issues as they report a comparative analysis of the predictive
power of post-HCT chimerism versus post-transplantation
PCR-based MRD assessment [5]. They add further informa-DOI of original article: http://dx.doi.org/10.1016/j.bbmt.2014.05.026.
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http://dx.doi.org/10.1016/j.bbmt.2014.07.026tion by correlating chimerism results from cell subsets
(CD8þ, CD19þ, and CD34þ cells) with outcome. Increasing
recipient chimerism in any cell subset predicted relapse and
poor survival. Measurements of chimerism in bone marrow
(BM) detected risk of relapse 2 to 3 months earlier than pe-
ripheral blood and was more sensitive (79% versus 55%;
P ¼ .06) but less speciﬁc (70% versus 87%; P ¼ .012). MRD
analysis after HCT was performed on a small subset of the
cohort (n ¼ 22) and found to be highly sensitive (86%) and
speciﬁc (95%) for relapse prediction, but because of low
numbers, the meaning of this ﬁnding is unclear.
Where does this leave us in 2014? Should we monitor
with chimerism or MRD, and if we ﬁnd our patient is high
risk with these measures, do interventions change
outcomes? Early work by Bader et al. showed that frequent
monitoring with chimerism could identify a portion of pa-
tients destined to relapse [4]. “Immunotherapy” with rapid
withdrawal of immune suppression and/or donor lympho-
cyte infusions (DLI) salvaged about a one third of patients.
But this approach is challengingdit requires frequent
(weekly to biweekly) chimerism assessments, and because
those who undergo transplantation for ALL most often
relapse between 6 and 18 months after the procedure, this
would mean staying close to transplantation centers or lots
of sample shipping for an extended time. Terwey et al.
showed that BM testing can be more accurate and detect
issues earlier, but frequent BM assessments after trans-
plantation are burdensome and run into similar problems for
most programs. The biggest challenge with chimerism
monitoring, however, is that it is not as sensitive or as spe-
ciﬁc as one would desire, and because current interventions
of immune withdrawal/DLI can be dangerous, the higher the
predictive power of a test, the better.
So what about MRD monitoring for relapse prediction?
Comparisons between the techniques are few, but Terwey
et al. showed better sensitivity with MRD compared with
chimerism. A weakness with this paper is that the number
of patients assessed for MRD is small (n ¼ 22), and more
studies are required to have conﬁdence in this measure. Is
this the best measure? Children’s Oncology Group/Pediatric
Blood and Marrow Transplant Consortium researchers
M.A. Pulsipher / Biol Blood Marrow Transplant 20 (2014) 1461e14641462showed that pretransplantation MRD in combination with
post-transplantation lack of graft-versus-host disease was
more predictive of relapse than post-transplantation MRD
[6]. Balduzzi et al. showed that MRD after transplantation
for ALL may be predictive, but the predictive power was
only strong after 6 months, with many early false positives
[7]. Deep-sequencing MRD techniques looking at immune
globulin rearrangements are beginning to be tested, and
early studies seem highly promising, but they are small [8].
More work needs to be done with larger numbers of pa-
tients to deﬁne the best techniques, but we have tools now
that can very accurately deﬁne who will relapse after
transplantation.
The key question remaining, then, is whether we can
offer interventions for high-risk patients that will impact
survival. A sobering study was published by Lankester
et al., where a cohort of patients at very high risk of relapse
due to MRD were treated with preemptive intervention
with immunosuppression tapering and/or DLI. Although
patients identiﬁed as high risk lived longer after inter-
vention, they eventually relapsed [9]. Very higherisk
biology is very difﬁcult to cure. But with recent exciting
advances with immunologically based approaches, such as
chimeric antigen receptor (CAR) T cells [10], bispeciﬁc
T cell engagers [11], and advanced conjugated immuno-
toxins (eg, moxetumomab [12] and inotuzumab [13]),
there is a strong possibility that effective approaches to
salvage therapy are possible. Deciding the appropriate risk
proﬁle (MRD before and/or after HCT will be part of this)
and best timing of intervention, followed by testing the
most promising of these agents in studies designed to
prevent relapse of high-risk ALL patients after HCT, are key
research priorities and challenges we must tackle in the
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